Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer

Here we identified a pair of new, distinct 10-gene signatures (the EPI<sup>S</sup> vs. the TME<sup>S</sup>) capable of distinguishing the cellular contribution of the tumor EPI vs. the TME in determining CRC prognosis and therapeutic outcomes. With targeted approaches emerging to address both tumor epithelial cells and the TME, the EPI<sup>S</sup> vs. TME<sup>S</sup> signature scores may have a novel biomarker role to permit optimization of CRC therapy by identifying sensitive vs. resistant subpopulations.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2025-03-12
DOI
https://doi.org/10.1186/s12885-025-13829-2
Citations
3
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
3.14

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer

Mingli Yang, Ramani Soundararajan, Sanjay Goel, Ashley J. Alden et al.
3 citations
BMC Cancer
Colorectal Cancer Treatments and Studies
3.14
article

Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer

Mingli Yang, Ramani Soundararajan, Sanjay Goel, Ashley J. Alden, Michelle M. Maurin, Michael Nebozhyn, Michael J. Schell, Andrey Loboda, Lance Pflieger, Emil Lou, Nishant Gandhi, George W. Sledge, Domenico Coppola, Heiman Wang, Moh’d Khushman, Andrew Elliott, Jetsen Rodriguez Silva, W. J. Pledger, Timothy Joseph Yeatman
article en
3 citations

Abstract

Here we identified a pair of new, distinct 10-gene signatures (the EPI<sup>S</sup> vs. the TME<sup>S</sup>) capable of distinguishing the cellular contribution of the tumor EPI vs. the TME in determining CRC prognosis and therapeutic outcomes. With targeted approaches emerging to address both tumor epithelial cells and the TME, the EPI<sup>S</sup> vs. TME<sup>S</sup> signature scores may have a novel biomarker role to permit optimization of CRC therapy by identifying sensitive vs. resistant subpopulations.

BMC CancerVol. 25(1)
Rutgers, The State University of New Jersey (US), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Washington University in St. Louis (US), University of South Florida (US), Tampa General Hospital (US), Moffitt Cancer Center (US), Florida Digestive Health Specialists (US), Université Bourgogne Franche-Comté (FR), University of Minnesota Medical Center (US), Caris Life Sciences (United States) (US)
National Institutes of Health
Good health and well-being
Openalex Percentile: Top 9%
Colorectal Cancer Treatments and Studies
3.14
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.